ERBB2 and breast carcinoma: Larger studies are needed to further evaluate the efficacy of neoadjuvant anti-HER-2 therapy combined with chemotherapy in Chinese patients with HER-2-positive breast cancer and the selection of surgical timing for patients receiving neoadjuvant chemotherapy combined with anti-HER-2 treatment.